{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:54Z","timestamp":1790820654430,"version":"4.1.0"},"reference-count":140,"publisher":"Bentham Science Publishers Ltd.","issue":"31","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Oral anticancer therapy faces several drawbacks of low aqueous solubility, poor and irregular absorption from gastro-intestinal sites, high first-pass metabolism, food-influenced absorption, non-targeted delivery, severe systemic and local adverse effects, etc. Enhancement of oral bioavailability could reduce the drug load and associated adverse effects. Self-emulsifying drug delivery systems (SEDDS) can enhance in-vivo solubility and drug absorption from the gastrointestinal tract, bypass liver metabolism by lymphatic absorption and inhibit efflux transport. All these phenomena ultimately result in improved oral bioavailability. Anticancer drug delivery using the SEDDS has shown promising results for bioavailability and pharmacodynamic response. A handful number of researches have produced evidence of the successful loading of anticancer agents in SEDDS-based formulations. Various potent and established chemotherapeutic agents such as docetaxel, paclitaxel, etoposide, 5 Fluorouracil, doxorubicin etc. have been successfully formulated and evaluated. Improved bioavailability and reduction of dose might be possible by SEDDS. It could be effective for low-dose drugs. But, excessive surfactant-cosurfactant concentration, lacking predictive in-vitro models and adequate IVIVC, unavailability of toxicity data are certain challenges for future researchers. To date, no clinical trials have been recorded with anticancer drug loaded SEDDS. To avail the benefits of anticancer SEDDS, overcoming the challenges and further progression to clinical studies are required.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Hospital based retrospective, observational study in which all the confirmed cases of CSC (272) seen between 2010 and 2019 were included. Supplementary data was collected on follow up visits or through telephonic calls.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The male: female ratio was 17:1; low socio-economic status was (155; 73.45%), and occupations such as drivers (61; 28.9%) and outdoor laborers (59; 27.96%) were the most commonly affected. The majority (78.05%; 185) were single expatriates. Financial worries (105; 50.72%) constituted the leading cause of stress. The usage of corticosteroids (83; 30.51%), nasal decongestants (14.70%) or both (17; 6.25%) within one year was common; mostly (82; 30.14%) for rhinitis\/respiratory states, though grossly under-recognized. Muscle relaxants and psychotropic medications were the other major medications used by 24 (8.82%) and 25 (9.19%) cases prior to CSC. Seven of 15 women had at least one condition that alters the endocrinal milieu: Pregnancy (3), recent child birth (1), erratic oral contraceptive intake (1), menopause with liver dysfunction (1), hormone replacement therapy for menopause and endometriosis (1), ovarian cyst and infertility (1) hypothyroidism (3), and Cushing syndrome (1). Chronic\/ recurrent forms were seen in 31.08%. There were too few glaucoma patients despite both CSC and glaucoma being common among our patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/03666220606143443","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:40:53Z","timestamp":1654598453000},"page":"2538-2553","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints\nand Recent Development"],"prefix":"10.2174","volume":"28","author":[{"given":"Mrugank","family":"Pandya","sequence":"first","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, Vile Parle West, Mumbai 400056,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bappaditya","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, Vile Parle West, Mumbai 400056,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikar","family":"Ganti","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, Vile Parle West, Mumbai 400056,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jddst.2018.01.013","volume":"44","author":"Rohrer J.","year":"2018","unstructured":"Rohrer J.; Zupan\u010di\u010d O.; Het\u00e9nyi G.; Kurpiers M.; Bernkop-Schn\u00fcrch A.; Design and evaluation of SEDDS exhibiting high emulsifying properties. J Drug Deliv Sci Technol 2018,44,366-372","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1080\/10717544.2016.1214990","volume":"23","author":"Chatterjee B.","year":"2016","unstructured":"Chatterjee B.; Almurisi H.S.; Dukhan A.M.; Mandal U.K.; Sengupta P.; Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Deliv 2016,23(9),3639-3652","journal-title":"Drug Deliv"},{"key":"ref=3","first-page":"42","volume":"2","author":"Patil S.L.","year":"2012","unstructured":"Patil S.L.; Nigade P.M.; Tiwari S.S.; Self emulsifying drug delivery system (SEDDS): A Review. Int J Pharm Biol Sci 2012,2(2),42-52","journal-title":"Int J Pharm Biol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.drudis.2010.08.007","volume":"15","author":"Kohli K.","year":"2010","unstructured":"Kohli K.; Chopra S.; Dhar D.; Arora S.; Khar R.K.; Self-emulsifying drug delivery systems: An approach to enhance oral bioavailability. Drug Discov Today 2010,15(21-22),958-965","journal-title":"Drug Discov Today"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0378-5173(00)00614-1","volume":"212","author":"Kommuru T.R.","year":"2001","unstructured":"Kommuru T.R.; Gurley B.; Khan M.A.; Reddy I.K.; Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int J Pharm 2001,212(2),233-246","journal-title":"Int J Pharm"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4172\/2157-7463.1000124","volume":"3","author":"Fakruddin M.D.","year":"2012","unstructured":"Fakruddin M.D.; Biosurfactant: production and application. J Pet Environ Biotechnol 2012,3(4),124","journal-title":"J Pet Environ Biotechnol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/pharmaceutics13071024","volume":"13","author":"Dinshaw I.J.","year":"2021","unstructured":"Dinshaw I.J.; Ahmad N.; Salim N.; Nanoemulsions: A review on the conceptualization of treatment for psoriasis using a \u2018green\u2019 surfactant with low-energy emulsification method. Pharmaceutics 2021,13(7),1024","journal-title":"Pharmaceutics"},{"key":"ref=8","first-page":"651","volume":"4","author":"Kuruvila F.S.","year":"2017","unstructured":"Kuruvila F.S.; Mathew F.; Kuppuswamy S.; Solid self nanoemulsifying drug delivery system (Snedds) devolopment, applications and future perspective\u202f: A review. Indo Am J Pharm Sci 2017,4(03),651-669","journal-title":"Indo Am J Pharm Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1208\/s12249-019-1335-x","volume":"20","author":"Rani S.","year":"2019","unstructured":"Rani S.; Rana R.; Saraogi G.K.; Kumar V.; Gupta U.; Self-Emulsifying oral lipid drug delivery systems: Advances and challenges. AAPS PharmSciTech 2019,20(3),129","journal-title":"AAPS PharmSciTech"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1166\/jbn.2017.2385","volume":"13","author":"Ge L.","year":"2017","unstructured":"Ge L.; You X.; Zhang Y.; Development of self-emulsifying nanoplatform as anti-diabetic sulfonylurea carrier for oral diabetes therapy. J Biomed Nanotechnol 2017,13(8),931-945","journal-title":"J Biomed Nanotechnol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2018.06.005","volume":"547","author":"Zaichik S.","year":"2018","unstructured":"Zaichik S.; Steinbring C.; Menzel C.; Development of self-emulsifying drug delivery systems (SEDDS) for ciprofloxacin with improved mucus permeating properties. Int J Pharm 2018,547(1-2),282-290","journal-title":"Int J Pharm"},{"key":"ref=12","first-page":"283","volume":"7","author":"Jangipuria F.","year":"2015","unstructured":"Jangipuria F.; Londhe V.; Solubility enhancement of Lurasidone hydrochloride by preparing SMEDDS. Int J Pharm Pharm Sci 2015,7(11),283-288","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/10837450.2015.1089899","volume":"22","author":"Kazi M.","year":"2017","unstructured":"Kazi M.; Al-Amri K.A.; Alanazi F.K.; The role of lipid-based drug delivery systems for enhancing solubility of highly selective antiviral agent acyclovir. Pharm Dev Technol 2017,22(3),312-321","journal-title":"Pharm Dev Technol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cplett.2010.01.001","volume":"487","author":"Banerjee S.","year":"2010","unstructured":"Banerjee S.; Sengupta P.S.; Mukherjee A.K.; A detailed theoretical DFT study of the hydrolysis mechanism of orally active anticancer drug ZD0473. Chem Phys Lett 2010,487(1\u20133),108-115","journal-title":"Chem Phys Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1039\/c0dt00292e","volume":"39","author":"Wheate N.J.","year":"2010","unstructured":"Wheate N.J.; Walker S.; Craig G.E.; Oun R.; The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010,39(35),8113-8127","journal-title":"Dalton Trans"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14712591003586806","volume":"10","author":"Minagar A.","year":"2010","unstructured":"Minagar A.; Alexander J.S.; Sahraian M.A.; Zivadinov R.; Alemtuzumab and multiple sclerosis: Therapeutic application. Expert Opin Biol Ther 2010,10(3),421-429","journal-title":"Expert Opin Biol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nmeth.3891","volume":"13","author":"Cranfill P.J.","year":"2016","unstructured":"Cranfill P.J.; Sell B.R.; Baird M.A.; Quantitative assessment of fluorescent proteins. Nat Methods 2016,13(7),557-562","journal-title":"Nat Methods"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","volume":"14","author":"Westphal M.","year":"2013","unstructured":"Westphal M.; Yl\u00e4-Herttuala S.; Martin J.; Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol 2013,14(9),823-833","journal-title":"Lancet Oncol"},{"key":"ref=19","first-page":"913","volume":"1","author":"Shahshahan M.A.","year":"2011","unstructured":"Shahshahan M.A.; Beckley M.N.; Jazirehi A.R.; Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: Basic and clinical aspects. Am J Cancer Res 2011,1,913-924","journal-title":"Am J Cancer Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","volume":"197","author":"Morales A.","year":"2017","unstructured":"Morales A.; Eidinger D.; Bruce A.W.; Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol 2017,197(2S),S142-S145","journal-title":"J Urol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"108505","DOI":"10.1016\/j.steroids.2019.108505","volume":"152","author":"Birudukota N.","year":"2019","unstructured":"Birudukota N.; Mudgal M.M.; Shanbhag V.; Discovery and development of azasteroids as anticancer agents. Steroids 2019,152,108505","journal-title":"Steroids"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"Zimmer L.","year":"2016","unstructured":"Zimmer L.; Goldinger S.M.; Hofmann L.; Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016,60,210-225","journal-title":"Eur J Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbacli.2015.04.001","volume":"3","author":"Neves H.","year":"2015","unstructured":"Neves H.; Kwok H.F.; Recent advances in the field of anti-cancer immunotherapy. BBA Clin 2015,3,280-288","journal-title":"BBA Clin"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","volume":"170","author":"Thanki K.","year":"2013","unstructured":"Thanki K.; Gangwal R.P.; Sangamwar A.T.; Jain S.; Oral delivery of anticancer drugs: Challenges and opportunities. J Control Release 2013,170(1),15-40","journal-title":"J Control Release"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.88412","author":"AboulFotouh K.","year":"2020","unstructured":"AboulFotouh K.; Allam A.; El-Badry M.; Self-emulsifying drug delivery systems: Easy to prepare multifunctional vectors for efficient oral delivery. Current and Future Aspects Nanomedicines 2020","journal-title":"Current and Future Aspects Nanomedicines"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijpharm.2015.12.054","volume":"499","author":"Kuo Y.C.","year":"2016","unstructured":"Kuo Y.C.; Cheng S.J.; Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation. Int J Pharm 2016,499(1-2),10-19","journal-title":"Int J Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11095-010-0110-1","volume":"27","author":"Abu Lila A.S.","year":"2010","unstructured":"Abu Lila A.S.; Ishida T.; Kiwada H.; Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 2010,27(7),1171-1183","journal-title":"Pharm Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3762\/bjoc.11.22","volume":"11","author":"\u00dcnal H.","year":"2015","unstructured":"\u00dcnal H.; \u00d6zt\u00fcrk N.; Bilensoy E.; Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin. Beilstein J Org Chem 2015,11,204-212","journal-title":"Beilstein J Org Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1208\/s12249-015-0370-5","volume":"17","author":"Truong D.H.","year":"2016","unstructured":"Truong D.H.; Tran T.H.; Ramasamy T.; Development of solid self-emulsifying formulation for improving the oral bioavailability of erlotinib. AAPS PharmSciTech 2016,17(2),466-473","journal-title":"AAPS PharmSciTech"},{"key":"ref=30","first-page":"7","volume":"2","author":"Kumar A.","year":"2010","unstructured":"Kumar A.; Sharma S.; Kamble R.; Self emulsifying drug delivery system (SEDDS): Future aspects. Int J Pharm Pharm Sci 2010,2(4),7-13","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3238\/arztebl.2019.0775","volume":"116","author":"Schlichtig K.","year":"2019","unstructured":"Schlichtig K.; D\u00fcrr P.; D\u00f6rje F.; Fromm M.F.; Neworal anti-cancer drugs and medications safety. Dtsch Arztebl Int 2019,116(46),775-782","journal-title":"Dtsch Arztebl Int"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4324\/9780203994559-14","volume":"262","author":"Barclay C.","year":"2018","unstructured":"Barclay C.; 1st Ed. In: Practitioner. Routledge 2018,262,25"},{"key":"ref=33","first-page":"HS-9","volume":"44","author":"Thomas S.A.","year":"2019","unstructured":"Thomas S.A.; John T.; Criner E.; Nguyen T.M.; Challenges to oral chemotherapy adherence. US Pharm 2019,44(6),HS-9-HS-12","journal-title":"US Pharm"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics11030132","volume":"11","author":"Tran P.","year":"2019","unstructured":"Tran P.; Pyo Y.C.; Kim D.H.; Lee S.E.; Kim J.K.; Park J.S.; Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics 2019,11(3),1-26","journal-title":"Pharmaceutics"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12121175","volume":"12","author":"Markovic M.","year":"2020","unstructured":"Markovic M.; Zur M.; Ragatsky I.; Cviji\u0107 S.; Dahan A.; Bcs class iv oral drugs and absorption windows: Regional-dependent intestinal permeability of furosemide. Pharmaceutics 2020,12(12),1-16","journal-title":"Pharmaceutics"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1517\/17425247.2015.1060219","volume":"12","author":"Sandhu P.S.","year":"2015","unstructured":"Sandhu P.S.; Beg S.; Mehta F.; Singh B.; Trivedi P.; Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: Implications on cytotoxicity and biopharmaceutical performance. Expert Opin Drug Deliv 2015,12(11),1809-1822","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jphp.13072","volume":"71","author":"Pollard J.","year":"2019","unstructured":"Pollard J.; Rajabi-Siahboomi A.; Badhan R.K.S.; Mohammed A.R.; Perrie Y.; High-throughput screening of excipients with a biological effect: A kinetic study on the effects of surfactants on efflux-mediated transport. J Pharm Pharmacol 2019,71(6),889-897","journal-title":"J Pharm Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ijpharm.2019.05.033","volume":"566","author":"Al-Ali A.A.A.","year":"2019","unstructured":"Al-Ali A.A.A.; Nielsen R.B.; Steffansen B.; Holm R.; Nielsen C.U.; Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption. Int J Pharm 2019,566,410-433","journal-title":"Int J Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejpb.2010.06.008","volume":"76","author":"Hanke U.","year":"2010","unstructured":"Hanke U.; May K.; Rozehnal V.; Nagel S.; Siegmund W.; Weitschies W.; Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 2010,76(2),260-268","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","volume":"14","author":"Bansal T.","year":"2009","unstructured":"Bansal T.; Akhtar N.; Jaggi M.; Khar R.K.; Talegaonkar S.; Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009,14(21-22),1067-1074","journal-title":"Drug Discov Today"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"Von Hoff D.D.","year":"2013","unstructured":"Von Hoff D.D.; Ervin T.; Arena F.P.; Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013,369(18),1691-1703","journal-title":"N Engl J Med"},{"key":"ref=42","first-page":"5114","volume":"63","author":"Gallo J.M.","year":"2003","unstructured":"Gallo J.M.; Li S.; Guo P.; Reed K.; Ma J.; The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003,63(16),5114-5117","journal-title":"Cancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3892\/or.2014.3344","volume":"32","author":"Song R.F.","year":"2014","unstructured":"Song R.F.; Li X.J.; Cheng X.L.; Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors. Oncol Rep 2014,32(4),1481-1488","journal-title":"Oncol Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"8511","DOI":"10.1016\/j.biomaterials.2013.07.075","volume":"34","author":"Cui Y.","year":"2013","unstructured":"Cui Y.; Xu Q.; Chow P.K.H.; Wang D.; Wang C.H.; Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013,34(33),8511-8520","journal-title":"Biomaterials"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S17336","volume":"6","author":"Atyabi F.","year":"2011","unstructured":"Atyabi F.; Sobhani M.; Adeli R.; Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. Int J Nanomedicine 2011,6,705-719","journal-title":"Int J Nanomedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.nano.2013.07.018","volume":"10","author":"Jing X.","year":"2014","unstructured":"Jing X.; Deng L.; Gao B.; A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel. Nanomedicine 2014,10(2),371-380","journal-title":"Nanomedicine"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1000164","DOI":"10.4172\/2157-7439.1000164","volume":"4","author":"Ma P.","year":"2013","unstructured":"Ma P.; Mumper R.J.; Paclitaxel nano-delivery systems: A comprehensive review. J Nanomed Nanotechnol 2013,4(2),1000164","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ajps.2018.10.003","volume":"14","author":"Ding D.","year":"2019","unstructured":"Ding D.; Sun B.; Cui W.; Integration of phospholipid-drug complex into self-nanoemulsifying drug delivery system to facilitate oral delivery of paclitaxel. Asian J Pharm Sci 2019,14(5),552-558","journal-title":"Asian J Pharm Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13346-016-0342-7","volume":"7","author":"Li Z.","year":"2017","unstructured":"Li Z.; Zhang W.; Gao Y.; Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs. Drug Deliv Transl Res 2017,7(1),100-110","journal-title":"Drug Deliv Transl Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s13346-016-0318-7","volume":"6","author":"Dangre P.","year":"2016","unstructured":"Dangre P.; Gilhotra R.; Dhole S.; Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability. Drug Deliv Transl Res 2016,6(5),610-621","journal-title":"Drug Deliv Transl Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1208\/s12249-012-9865-5","volume":"13","author":"Beg S.","year":"2012","unstructured":"Beg S.; Swain S.; Singh H.P.; Patra ChN.; Rao M.E.; Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech 2012,13(4),1416-1427","journal-title":"AAPS PharmSciTech"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.colsurfb.2012.05.019","volume":"100","author":"Bandyopadhyay S.","year":"2012","unstructured":"Bandyopadhyay S.; Katare O.P.; Singh B.; Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces 2012,100,50-61","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/aps.2010.55","volume":"31","author":"Yu J.N.","year":"2010","unstructured":"Yu J.N.; Zhu Y.; Wang L.; Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate\/] phospholipid-mixed micelles. Acta Pharmacol Sin 2010,31(6),759-764","journal-title":"Acta Pharmacol Sin"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","volume":"26","author":"Ojima I.","year":"2016","unstructured":"Ojima I.; Lichtenthal B.; Lee S.; Wang C.; Wang X.; Taxane anticancer agents: A patent perspective. Expert Opin Ther Pat 2016,26(1),1-20","journal-title":"Expert Opin Ther Pat"},{"key":"ref=55","first-page":"12","volume":"32","author":"Ganellin C.R.","year":"2010","unstructured":"Ganellin C.R.; Analogue-based drug discovery. Chem Int Newsmag IUPAC 2010,32(4),12-15","journal-title":"Chem Int Newsmag IUPAC"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.2147\/IJN.S164518","volume":"13","author":"Sohail M.F.","year":"2018","unstructured":"Sohail M.F.; Rehman M.; Sarwar H.S.; Advancements in the oral delivery of Docetaxel: Challenges, current state-of-the-art and future trends. Int J Nanomedicine 2018,13,3145-3161","journal-title":"Int J Nanomedicine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1021\/mp4006968","volume":"11","author":"Naguib Y.W.","year":"2014","unstructured":"Naguib Y.W.; Rodriguez B.L.; Li X.; Hursting S.D.; Williams R.O.; Cui Z.; Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm 2014,11(4),1239-1249","journal-title":"Mol Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mabi.201500317","volume":"16","author":"Guo Y.","year":"2016","unstructured":"Guo Y.; Zhang P.; Zhao Q.; Wang K.; Luan Y.; Reduction-sensitive polymeric micelles based on docetaxel-polymer conjugates via disulfide linker for efficient cancer therapy. Macromol Biosci 2016,16(3),420-431","journal-title":"Macromol Biosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.03.017","volume":"543","author":"Li B.","year":"2018","unstructured":"Li B.; Zhang X.X.; Huang H.Y.; Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel. Int J Pharm 2018,543(1-2),8-20","journal-title":"Int J Pharm"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijpharm.2013.05.034","volume":"452","author":"Seo Y.G.","year":"2013","unstructured":"Seo Y.G.; Kim D.H.; Ramasamy T.; Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm 2013,452(1-2),412-420","journal-title":"Int J Pharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.1016\/j.biomaterials.2011.09.017","volume":"32","author":"Chang R.S.","year":"2011","unstructured":"Chang R.S.; Suh M.S.; Kim S.; Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials 2011,32(36),9785-9795","journal-title":"Biomaterials"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.biopha.2018.11.110","volume":"109","author":"Akhtartavan S.","year":"2019","unstructured":"Akhtartavan S.; Karimi M.; Karimian K.; Azarpira N.; Khatami M.; Heli H.; Evaluation of a self-nanoemulsifying docetaxel delivery system. Biomed Pharmacother 2019,109,2427-2433","journal-title":"Biomed Pharmacother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","volume":"34","author":"Hande K.R.","year":"1998","unstructured":"Hande K.R.; Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998,34(10),1514-1521","journal-title":"Eur J Cancer"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000219422","volume":"1","author":"Fuchs M.","year":"1960","unstructured":"Fuchs M.; The clinical pharmacology of hydrochlorothiazide. Chemotherapia (Basel) 1960,1(4-5),231-238","journal-title":"Chemotherapia (Basel)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3201\/eid0904.020268","volume":"9","author":"McCaig L.F.","year":"2003","unstructured":"McCaig L.F.; Besser R.E.; Hughes J.M.; Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003,9(4),432-437","journal-title":"Emerg Infect Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00003088-200443070-00002","volume":"43","author":"Toffoli G.","year":"2004","unstructured":"Toffoli G.; Corona G.; Basso B.; Boiocchi M.; Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004,43(7),441-466","journal-title":"Clin Pharmacokinet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9010050","volume":"9","author":"Alfei S.","year":"2020","unstructured":"Alfei S.; Marengo B.; Domenicotti C.; Polyester-based dendrimer nanoparticles combined with etoposide have an improved cytotoxic and pro-oxidant effect on human neuroblastoma cells. Antioxidants 2020,9(1),1-23","journal-title":"Antioxidants"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4274\/tjps.galenos.2018.21043","volume":"16","author":"Thiyagarajan A.","year":"2019","unstructured":"Thiyagarajan A.; Saravanabhavan S.; Thangarasu V.; Preparation and biopharmaceutical evaluation of novel polymeric nanoparticles containing etoposide for targeting cancer cells. Turkish J Pharm Sci 2019,16(2),132-140","journal-title":"Turkish J Pharm Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tiv.2017.03.007","volume":"41","author":"Le Roux G.","year":"2017","unstructured":"Le Roux G.; Moche H.; Nieto A.; Benoit J.P.; Nesslany F.; Lagarce F.; Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicol Vitr 2017,41,189-199","journal-title":"Toxicol Vitr"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5530\/srp.2020.2.55","volume":"11","author":"Ali M.M.","year":"2020","unstructured":"Ali M.M.; Rajab N.A.; Abdulrasool A.A.; Etoposide-loaded gold nanoparticles: Preparation, characterization, optimization and cytotoxicity assay. Syst Rev Pharm 2020,11(2),372-381","journal-title":"Syst Rev Pharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1039\/C7TB01628J","volume":"5","author":"Wu B.","year":"2017","unstructured":"Wu B.; Zhu R.; Wang M.; Liang P.; Qian Y.; Wang S.; Fluorescent carbon dots from antineoplastic drug etoposide for bioimaging in vitro and in vivo. J Mater Chem B Mater Biol Med 2017,5(38),7796-7800","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1166\/jbn.2013.1613","volume":"9","author":"Akhtar N.","year":"2013","unstructured":"Akhtar N.; Talegaonkar S.; Khar R.K.; Jaggi M.; Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: In vitro cell line and in vivo pharmacokinetic investigation. J Biomed Nanotechnol 2013,9(7),1216-1229","journal-title":"J Biomed Nanotechnol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1517\/13543776.2011.561784","volume":"21","author":"Akhtar N.","year":"2011","unstructured":"Akhtar N.; Ahad A.; Khar R.K.; The emerging role of P-glycoprotein inhibitors in drug delivery: A patent review. Expert Opin Ther Pat 2011,21(4),561-576","journal-title":"Expert Opin Ther Pat"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.4155\/tde.11.128","volume":"2","author":"Griffin B.T.","year":"2011","unstructured":"Griffin B.T.; O\u2019Driscoll C.M.; Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv 2011,2(12),1633-1653","journal-title":"Ther Deliv"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","volume":"55","author":"Ishikawa T.","year":"1998","unstructured":"Ishikawa T.; Utoh M.; Sawada N.; Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998,55(7),1091-1097","journal-title":"Biochem Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e0159052","DOI":"10.1371\/journal.pone.0159052","volume":"11","author":"Simon N.","year":"2016","unstructured":"Simon N.; Vasseur M.; Pinturaud M.; Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: A prospective, controlled, parallel study. PLoS One 2016,11(7),e0159052","journal-title":"PLoS One"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0378-5173(85)90143-7","volume":"24","author":"Buur A.","year":"1985","unstructured":"Buur A.; Bundgaard H.; Falch E.; Prodrugs of 5-fluorouracil. IV. Hydrolysis kinetics, bioactivation and physicochemical properties of various N-acyloxymethyl derivatives of 5-fluorouracil. Int J Pharm 1985,24(1),43-60","journal-title":"Int J Pharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11095-017-2283-3","volume":"35","author":"Abd-Rabou A.A.","year":"2018","unstructured":"Abd-Rabou A.A.; Bharali D.J.; Mousa S.A.; Taribavirin and 5-Fluorouracil-Loaded pegylated-lipid nanoparticle synthesis, p38 docking, and antiproliferative effects on MCF-7 breast Cancer. Pharm Res 2018,35(4),76","journal-title":"Pharm Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jsps.2014.11.010","volume":"23","author":"Tummala S.","year":"2015","unstructured":"Tummala S.; Satish Kumar M.N.; Prakash A.; Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 2015,23(3),308-314","journal-title":"Saudi Pharm J"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.msec.2019.109828","volume":"103","author":"Ra\u021b\u0103 D.M.","year":"2019","unstructured":"Ra\u021b\u0103 D.M.; Cadinoiu A.N.; Atanase L.I.; \u201cIn vitro\u201d behaviour of aptamer-functionalized polymeric nanocapsules loaded with 5-fluorouracil for targeted therapy. Mater Sci Eng C 2019,103,109828","journal-title":"Mater Sci Eng C"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.carbpol.2016.09.096","volume":"157","author":"Sauraj S.U.","year":"2017","unstructured":"Sauraj S.U.; Kumar S.U.; Gopinath P.; Negi Y.S.; Synthesis and bio-evaluation of xylan-5-fluorouracil-1-acetic acid conjugates as prodrugs for colon cancer treatment. Carbohydr Polym 2017,157,1442-1450","journal-title":"Carbohydr Polym"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.apsusc.2017.08.228","volume":"427","author":"Lima D.","year":"2018","unstructured":"Lima D.; Cala\u00e7a G.N.; Viana A.G.; Pess\u00f4a C.A.; Porphyran-capped gold nanoparticles modified carbon paste electrode: A simple and efficient electrochemical sensor for the sensitive determination of 5-fluorouracil. Appl Surf Sci 2018,427,742-753","journal-title":"Appl Surf Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.electacta.2015.08.036","volume":"178","author":"Satyanarayana M.","year":"2015","unstructured":"Satyanarayana M.; Goud K.Y.; Reddy K.K.; Gobi K.V.; Biopolymer stabilized nanogold particles on carbon nanotube support as sensing platform for electrochemical detection of 5-Fluorouracil in-vitro. Electrochim Acta 2015,178,608-616","journal-title":"Electrochim Acta"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.molliq.2014.10.013","volume":"200","author":"Shakeel F.","year":"2014","unstructured":"Shakeel F.; Haq N.; Al-Dhfyan A.; Alanazi F.K.; Alsarra I.A.; Double w\/o\/w nanoemulsion of 5-fluorouracil for self-nanoemulsifying drug delivery system. J Mol Liq 2014,200,183-190","journal-title":"J Mol Liq"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/cmdc.201100321","volume":"6","author":"Steinhagen H.","year":"2011","unstructured":"Steinhagen H.; The evolution of drug discovery: From traditional medicines to modern drugs. By Enrique Ravi\u00f1a. ChemMedChem 2011,6(9),1746-1747","journal-title":"ChemMedChem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"Tacar O.","year":"2013","unstructured":"Tacar O.; Sriamornsak P.; Dass C.R.; Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013,65(2),157-170","journal-title":"J Pharm Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"418","DOI":"10.21608\/ejh.2020.31011.1299","volume":"44","author":"Mansy M.","year":"2021","unstructured":"Mansy M.; Soliman M.; Mubarak R.; Shamel M.; The effect of EGF on VEGF expression on submandibular salivary gland of albino rats receiving doxorubicin. Egypt J Histol 2021,44(2),418-424","journal-title":"Egypt J Histol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"Chatterjee K.","year":"2010","unstructured":"Chatterjee K.; Zhang J.; Honbo N.; Karliner J.S.; Doxorubicin cardiomyopathy. Cardiology 2010,115(2),155-162","journal-title":"Cardiology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"120029","DOI":"10.1016\/j.ijpharm.2020.120029","volume":"592","author":"Moraes S.","year":"2021","unstructured":"Moraes S.; Marinho A.; Lima S.; Targeted nanostructured lipid carriers for doxorubicin oral delivery. Int J Pharm 2021,592,120029","journal-title":"Int J Pharm"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/21691401.2019.1581791","volume":"47","author":"Usmani A.","year":"2019","unstructured":"Usmani A.; Mishra A.; Arshad M.; Jafri A.; Development and evaluation of doxorubicin self nanoemulsifying drug delivery system with Nigella Sativa oil against human hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2019,47(1),933-944","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s11655-014-2024-y","volume":"20","author":"Tang T.Y.","year":"2014","unstructured":"Tang T.Y.; Li F.Z.; Afseth J.; Review of the regulations for clinical research in herbal medicines in USA. Chin J Integr Med 2014,20(12),883-893","journal-title":"Chin J Integr Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.matpr.2020.02.659","volume":"34","author":"Gopireddy R.R.","year":"2021","unstructured":"Gopireddy R.R.; Maruthapillai A.; Arockia Selvi J.; Mahapatra S.; Determination of potential genotoxic impurity hydrazine hydrate in ibrutinib by RP-liquid chromatography. Mater Today Proc 2021,34,430-436","journal-title":"Mater Today Proc"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bcp.12787","volume":"81","author":"de Vries R.","year":"2016","unstructured":"de Vries R.; Smit J.W.; Hellemans P.; Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. Br J Clin Pharmacol 2016,81(2),235-245","journal-title":"Br J Clin Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/1573412915666190314124932","volume":"15","author":"Alshetaili A.S.","year":"2019","unstructured":"Alshetaili A.S.; Ansari M.J.; Anwer M.K.; Enhanced oral bioavailability of ibrutinib encapsulated poly (Lactic-co-Glycolic Acid) nanoparticles: Pharmacokinetic evaluation in rats. Curr Pharm Anal 2019,15(6),661-668","journal-title":"Curr Pharm Anal"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s13346-020-00803-7","volume":"10","author":"Rangaraj N.","year":"2020","unstructured":"Rangaraj N.; Pailla S.R.; Shah S.; Prajapati S.; Sampathi S.; QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: Evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res 2020,10(5),1476-1494","journal-title":"Drug Deliv Transl Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"113878","DOI":"10.1016\/j.molliq.2020.113878","volume":"316","author":"S\u00e1nchez-Coronilla A.","year":"2020","unstructured":"S\u00e1nchez-Coronilla A.; Mart\u00edn E.I.; Fern\u00e1ndez-de-Cordova F.J.; Prado-Gotor R.; Hidalgo J.; Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia. J Mol Liq 2020,316,113878","journal-title":"J Mol Liq"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/jphp.12550","volume":"68","author":"Shakeel F.","year":"2016","unstructured":"Shakeel F.; Iqbal M.; Ezzeldin E.; Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol 2016,68(6),772-780","journal-title":"J Pharm Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.colsurfb.2017.02.012","volume":"153","author":"Thapa R.K.","year":"2017","unstructured":"Thapa R.K.; Kim J.H.; Jeong J.H.; Silver nanoparticle-embedded graphene oxide-methotrexate for targeted cancer treatment. Colloids Surf B Biointerfaces 2017,153,95-103","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=99","first-page":"16","volume":"124","author":"Weinblatt M.E.","year":"2013","unstructured":"Weinblatt M.E.; Methotrexate in rheumatoid arthritis: A quarter century of development. Trans Am Clin Climatol Assoc 2013,124,16-25","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12034-014-0030-5","volume":"37","author":"Musmade K.P.","year":"2014","unstructured":"Musmade K.P.; Deshpande P.B.; Musmade P.B.; Methotrexate-loaded biodegradable nanoparticles: Preparation, characterization and evaluation of its cytotoxic potential against U-343 MGa human neuronal glioblastoma cells. Bull Mater Sci 2014,37(4),945-951","journal-title":"Bull Mater Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"39482","DOI":"10.1039\/C5RA03546E","volume":"5","author":"Ray S.","year":"2015","unstructured":"Ray S.; Joy M.; Sa B.; Ghosh S.; Chakraborty J.; pH dependent chemical stability and release of methotrexate from a novel nanoceramic carrier. RSC Advances 2015,5(49),39482-39494","journal-title":"RSC Advances"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.3390\/pharmaceutics11020065","volume":"11","author":"Muntoni E.","year":"2019","unstructured":"Muntoni E.; Martina K.; Marini E.; Methotrexate-loaded solid lipid nanoparticles: Protein functionalization to improve brain biodistribution. Pharmaceutics 2019,11(2),E65","journal-title":"Pharmaceutics"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1039\/C7NJ04864E","volume":"42","author":"Rostamizadeh K.","year":"2018","unstructured":"Rostamizadeh K.; Manafi M.; Nosrati H.; Kheiri Manjili H.; Danafar H.; Methotrexate-conjugated mPEG-PCL copolymers: A novel approach for dual triggered drug delivery. New J Chem 2018,42(8),5937-5945","journal-title":"New J Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1177\/0885328217698063","volume":"31","author":"Gharebaghi F.","year":"2017","unstructured":"Gharebaghi F.; Dalali N.; Ahmadi E.; Danafar H.; Preparation of wormlike polymeric nanoparticles coated with silica for delivery of methotrexate and evaluation of anticancer activity against MCF7 cells. J Biomater Appl 2017,31(9),1305-1316","journal-title":"J Biomater Appl"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.2147\/IJN.S168400","volume":"13","author":"Pereira N.R.C.","year":"2018","unstructured":"Pereira N.R.C.; Loiola R.A.; Rodrigues S.F.; Mechanisms of the effectiveness of poly(\u03b5-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment. Int J Nanomedicine 2018,13,4563-4573","journal-title":"Int J Nanomedicine"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nano.2019.01.006","volume":"17","author":"Fratoddi I.","year":"2019","unstructured":"Fratoddi I.; Benassi L.; Botti E.; Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model. Nanomedicine 2019,17,276-286","journal-title":"Nanomedicine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1021\/acsomega.8b03212","volume":"4","author":"Saeednia L.","year":"2019","unstructured":"Saeednia L.; Yao L.; Cluff K.; Asmatulu R.; Sustained releasing of methotrexate from injectable and thermosensitive chitosan-carbon nanotube hybrid hydrogels effectively controls tumor cell growth. ACS Omega 2019,4(2),4040-4048","journal-title":"ACS Omega"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.2147\/IJN.S211014","volume":"14","author":"Kim D.S.","year":"2019","unstructured":"Kim D.S.; Cho J.H.; Park J.H.; Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate. Int J Nanomedicine 2019,14,4949-4960","journal-title":"Int J Nanomedicine"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"118905","DOI":"10.1016\/j.saa.2020.118905","volume":"245","author":"Preisz Z.","year":"2021","unstructured":"Preisz Z.; Kuns\u00e1gi-M\u00e1t\u00e9 S.; Effect of methotrexate and its photodegradation products on the temperature induced denaturation of human serum albumin. Spectrochim Acta A Mol Biomol Spectrosc 2021,245,118905","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"E365","DOI":"10.3390\/pharmaceutics12040365","volume":"12","author":"Park H.","year":"2020","unstructured":"Park H.; Ha E.S.; Kim M.S.; Current status of supersaturable self-emulsifying drug delivery systems. Pharmaceutics 2020,12(4),E365","journal-title":"Pharmaceutics"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1517\/17425247.3.1.97","volume":"3","author":"Gao P.","year":"2006","unstructured":"Gao P.; Morozowich W.; Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of. Expert Opin Drug Deliv 2006,3,97-110","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1021\/acs.molpharmaceut.8b00206","volume":"15","author":"Suys E.J.A.","year":"2018","unstructured":"Suys E.J.A.; Chalmers D.K.; Pouton C.W.; Porter C.J.H.; Polymeric precipitation inhibitors promote fenofibrate supersaturation and enhance drug absorption from a type IV lipid-based formulation polymeric precipitation inhibitors promote fenofibrate supersaturation and enhance drug absorption from a type IV lip. Mol Pharm 2018,15(6),2355-2371","journal-title":"Mol Pharm"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2018.11.006","volume":"142","author":"Joyce P.","year":"2019","unstructured":"Joyce P.; Dening T.J.; Meola T.R.; Solidification to improve the biopharmaceutical performance of SEDDS: Opportunities and challenges. Adv Drug Deliv Rev 2019,142,102-117","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40005-017-0372-2","volume":"48","author":"Ma X.","year":"2017","unstructured":"Ma X.; Williams R.O.; Polymeric nanomedicines for poorly soluble drugs in oral delivery systems\u202f: An update. J Pharm Investig 2017,48,61-75","journal-title":"J Pharm Investig"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1166\/jnn.2015.9248","volume":"15","author":"Cho H.Y.","year":"2015","unstructured":"Cho H.Y.; Choi J.H.; Oh I.J.; Lee Y.B.; Self-emulsifying drug delivery system for enhancing bioavailability and lymphatic delivery of tacrolimus. J Nanosci Nanotechnol 2015,15(2),1831-1841","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/02652048.2015.1057252","volume":"32","author":"Seo Y.G.","year":"2015","unstructured":"Seo Y.G.; Kim D.W.; Yousaf A.M.; Solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced oral bioavailability of poorly water-soluble tacrolimus: Physicochemical characterisation and pharmacokinetics. J Microencapsul 2015,32(5),503-510","journal-title":"J Microencapsul"},{"key":"ref=117","first-page":"18","volume":"4","author":"Shah Sanket P.","year":"2012","unstructured":"Shah Sanket P.; Shah Mansi D.; Agrawal Yadvendra K.; Self emulsifying drug delivery: A novel approach for enhancement of oral bioavailability of poorly soluble drugs. Int J Curr Pharm Res 2012,4(2),18-23","journal-title":"Int J Curr Pharm Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1208\/s12248-012-9433-7","volume":"15","author":"Thomas N.","year":"2013","unstructured":"Thomas N.; Holm R.; Garmer M.; Karlsson J.J.; M\u00fcllertz A.; Rades T.; Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J 2013,15(1),219-227","journal-title":"AAPS J"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/17425247.2011.548801","volume":"8","author":"Nokhodchi A.","year":"2011","unstructured":"Nokhodchi A.; Hentzschel C.M.; Leopold C.S.; Drug release from liquisolid systems\u202f: Speed it up, slow it down. Expert Opin Drug Deliv 2011,8(2),191-205","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22159\/ajpcr.2021.v14i8.41987","volume":"14","author":"Reddy M.R.","year":"2021","unstructured":"Reddy M.R.; Gubbiyappa K.S.; A comprehensive review on supersaturable self-nanoemulsifying drug delivery system. Asian J Pharm Clin Res 2021,14(8),40-44","journal-title":"Asian J Pharm Clin Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","volume":"60","author":"Trevaskis N.L.","year":"2008","unstructured":"Trevaskis N.L.; Charman W.N.; Porter C.J.H.; Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev 2008,60(6),702-716","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=122","first-page":"18","volume":"6","author":"Sun M.","year":"2011","unstructured":"Sun M.; Han J.; Guo X.; Design, preparation and in vitro evaluation of paclitaxel-loaded self-nanoemulsifying drug delivery system. Asian J Pharm Sci 2011,6(1),18-25","journal-title":"Asian J Pharm Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijpharm.2004.03.034","volume":"285","author":"Taha E.I.","year":"2004","unstructured":"Taha E.I.; Al-Saidan S.; Samy A.M.; Khan M.A.; Preparation and in vitro characterization of self-nanoemulsified drug delivery system (SNEDDS) of all-trans-retinol acetate. Int J Pharm 2004,285(1-2),109-119","journal-title":"Int J Pharm"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1208\/s12249-019-1319-x","volume":"20","author":"Beg S.","year":"2019","unstructured":"Beg S.; Kaur R.; Khurana R.K.; Rana V.; Sharma T.; Singh B.; QbD-Based development of cationic self-nanoemulsifying drug delivery systems of paclitaxel with improved biopharmaceutical attributes. AAPS PharmSciTech 2019,20(3),118","journal-title":"AAPS PharmSciTech"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1016\/j.xphs.2020.07.027","volume":"109","author":"Al-Kandari B.M.","year":"2020","unstructured":"Al-Kandari B.M.; Al-Soraj M.H.; Hedaya M.A.; Dual formulation and interaction strategies to enhance the oral bioavailability of paclitaxel. J Pharm Sci 2020,109(11),3386-3393","journal-title":"J Pharm Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"398","DOI":"10.18433\/jpps30097","volume":"21","author":"Khalid N.","year":"2018","unstructured":"Khalid N.; Sarfraz M.; Arafat M.; Akhtar M.; L\u00f6benberg R.; Ur Rehman N.; Nano-sized droplets of self-emulsifying system for enhancing oral bioavailability of chemotherapeutic agent VP-16 in Rats: A nano lipid carrier for BCS class IV drugs. J Pharm Pharm Sci 2018,21(1),398-408","journal-title":"J Pharm Pharm Sci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/02652048.2012.726280","volume":"30","author":"Quan Q.","year":"2013","unstructured":"Quan Q.; Kim D.W.; Marasini N.; Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. J Microencapsul 2013,30(4),307-314","journal-title":"J Microencapsul"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4314\/tjpr.v14i4.2","volume":"14","author":"Rao B.C.","year":"2015","unstructured":"Rao B.C.; Vidyadhara S.; Sasidhar R.L.; Chowdary Y.A.; Formulation and evaluation of liquid loaded tablets containing docetaxel-self nano emulsifying drug delivery systems. Trop J Pharm Res 2015,14(4),567-573","journal-title":"Trop J Pharm Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3109\/03639045.2012.718785","volume":"39","author":"Bourkaib N.","year":"2013","unstructured":"Bourkaib N.; Zhou J.; Yao J.; Fang Z.; Mezghrani O.; Combination of \u03b2-cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique. Drug Dev Ind Pharm 2013,39(6),918-927","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=130","first-page":"91","volume":"14","author":"Prasad D.","year":"2020","unstructured":"Prasad D.; Mohanta G.; Sudhakar M.; development and optimization of self-nanoemulsifying drug delivery system of ibrutinib. Asian J Pharm 2020,14(1),91-104","journal-title":"Asian J Pharm"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/jps.23858","volume":"103","author":"Tran T.H.","year":"2014","unstructured":"Tran T.H.; Guo Y.; Song D.; Bruno R.S.; Lu X.; Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability. J Pharm Sci 2014,103(3),840-852","journal-title":"J Pharm Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.nano.2013.12.010","volume":"10","author":"Jain A.K.","year":"2014","unstructured":"Jain A.K.; Thanki K.; Jain S.; Novel self-nanoemulsifying formulation of quercetin: Implications of pro-oxidant activity on the anticancer efficacy. Nanomedicine 2014,10(5),959-969","journal-title":"Nanomedicine"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/03639045.2016.1239732","volume":"43","author":"Shukla M.","year":"2017","unstructured":"Shukla M.; Jaiswal S.; Sharma A.; A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin. Drug Dev Ind Pharm 2017,43(5),847-861","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25071703","volume":"25","author":"Kazi M.","year":"2020","unstructured":"Kazi M.; Shahba A.A.; Alrashoud S.; Alwadei M.; Sherif A.Y.; Alanazi F.K.; Bioactive self-nanoemulsifying drug delivery systems (Bio-SNEDDS) for combined oral delivery of curcumin and piperine. Molecules 2020,25(7),1-24","journal-title":"Molecules"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.2147\/IJN.S25824","author":"Gong T.","year":"2011","unstructured":"Gong T.; Peng Q.; Shi S.; Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex. Int J Nanomedicine 2011,3405-3414","journal-title":"Int J Nanomedicine"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3109\/10717544.2013.878003","volume":"22","author":"Khan A.W.","year":"2015","unstructured":"Khan A.W.; Kotta S.; Ansari S.H.; Sharma R.K.; Ali J.; Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: Design, characterization, in vitro and in vivo evaluation. Drug Deliv 2015,22(4),552-561","journal-title":"Drug Deliv"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ijbiomac.2020.02.275","volume":"152","author":"Batool A.","year":"2020","unstructured":"Batool A.; Arshad R.; Razzaq S.; Nousheen K.; Kiani M.H.; Shahnaz G.; Formulation and evaluation of hyaluronic acid-based mucoadhesive self nanoemulsifying drug delivery system (SNEDDS) of tamoxifen for targeting breast cancer. Int J Biol Macromol 2020,152,503-515","journal-title":"Int J Biol Macromol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.2147\/IJN.S121114","volume":"11","author":"Pangeni R.","year":"2016","unstructured":"Pangeni R.; Choi S.W.; Jeon O.C.; Byun Y.; Park J.W.; Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: Preparation and in vivo evaluation. Int J Nanomedicine 2016,11,6379-6399","journal-title":"Int J Nanomedicine"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.colsurfb.2017.09.008","volume":"160","author":"Nazari-Vanani R.","year":"2017","unstructured":"Nazari-Vanani R.; Azarpira N.; Heli H.; Karimian K.; Sattarahmady N.; A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. Colloids Surf B Biointerfaces 2017,160,65-72","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.xphs.2020.01.010","volume":"109","author":"Nottingham E.","year":"2020","unstructured":"Nottingham E.; Sekar V.; Mondal A.; Safe S.; Rishi A.K.; Singh M.; The role of self-nanoemulsifying drug delivery systems of CDODA-Me in sensitizing erlotinib-resistant non-small cell lung cancer. J Pharm Sci 2020,109(6),1867-1882","journal-title":"J Pharm Sci"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/03666220606143443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205659\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/03666220606143443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T09:18:25Z","timestamp":1691745505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205659\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":140,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/03666220606143443","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}